Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
RANK-L and RANK: T cells, bone loss, and mammalian evolution.
Theill LE, Boyle WJ, Penninger JM. Theill LE, et al. Among authors: boyle wj. Annu Rev Immunol. 2002;20:795-823. doi: 10.1146/annurev.immunol.20.100301.064753. Epub 2001 Oct 4. Annu Rev Immunol. 2002. PMID: 11861618 Review.
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Eghbali-Fatourechi G, et al. Among authors: boyle wj. J Clin Invest. 2003 Apr;111(8):1221-30. doi: 10.1172/JCI17215. J Clin Invest. 2003. PMID: 12697741 Free PMC article.
Osteoclast differentiation and activation.
Boyle WJ, Simonet WS, Lacey DL. Boyle WJ, et al. Nature. 2003 May 15;423(6937):337-42. doi: 10.1038/nature01658. Nature. 2003. PMID: 12748652 Review.
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R. Lacey DL, et al. Among authors: boyle wj. Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. Nat Rev Drug Discov. 2012. PMID: 22543469 Review.
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Kostenuik PJ, et al. Among authors: boyle wj. J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112. J Bone Miner Res. 2009. PMID: 19016581 Free article.
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis.
Bolon B, Shalhoub V, Kostenuik PJ, Campagnuolo G, Morony S, Boyle WJ, Zack D, Feige U. Bolon B, et al. Among authors: boyle wj. Arthritis Rheum. 2002 Dec;46(12):3121-35. doi: 10.1002/art.10680. Arthritis Rheum. 2002. PMID: 12483715 Free article. Review. No abstract available.
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.
Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. Fata JE, et al. Among authors: boyle wj. Cell. 2000 Sep 29;103(1):41-50. doi: 10.1016/s0092-8674(00)00103-3. Cell. 2000. PMID: 11051546
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. Hofbauer LC, et al. Among authors: boyle wj. J Bone Miner Res. 2000 Jan;15(1):2-12. doi: 10.1359/jbmr.2000.15.1.2. J Bone Miner Res. 2000. PMID: 10646108 Review.
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.
Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. Kong YY, et al. Among authors: boyle wj. Nature. 1999 Jan 28;397(6717):315-23. doi: 10.1038/16852. Nature. 1999. PMID: 9950424
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V, Faust J, Boyle WJ, Dunstan CR, Kelley M, Kaufman S, Scully S, Van G, Lacey DL. Shalhoub V, et al. Among authors: boyle wj. J Cell Biochem. 1999 Feb 1;72(2):251-61. J Cell Biochem. 1999. PMID: 10022507
55 results
Jump to page
Feedback